The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. 

 -  2018 
<br/><br/>Available online from MWHC library: 1997 - present 
<br/><br/> CONCLUSIONS: We found no evidence of SNP interactions with statin usage for breast cancer risk in a population of 3374 individuals. These results suggest that genome-wide common genetic variants do not moderate the association between statin usage and breast cancer in the population of women in the Women's Health Initiative.  METHODS: To identify candidate gene-statin interactions, we tested interactions between 22 SNPS in nine candidate genes implicated in the effect of statins on lipid metabolism in 1687 cases and 1687 controls. We then evaluated statin use interaction with the remaining 30,380 SNPs available in this sample from the CGEMS GWAS study.  PURPOSE: Statins have been postulated to have chemopreventive activity against breast cancer. We evaluated whether germline genetic polymorphisms modified the relationship between statins and breast cancer risk using data from the Women's Health Initiative. We evaluated these interactions using both candidate gene and agnostic genome-wide approaches.  RESULTS: After adjusting for multiple comparisons, no SNP interactions with statin usage and risk of breast cancer were statistically significant in either the candidate genes or genome-wide approaches. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0167-6806 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Breast Neoplasms/dt [Drug Therapy]<br/>*Cholesterol/ge [Genetics]<br/>*Genetic Predisposition to Disease<br/>*Hydroxymethylglutaryl-CoA Reductase Inhibitors/ad [Administration & Dosage]<br/>Aged<br/>Anticholesteremic Agents/ad [Administration & Dosage]<br/>Anticholesteremic Agents/ae [Adverse Effects]<br/>Breast Neoplasms/ge [Genetics]<br/>Breast Neoplasms/pa [Pathology]<br/>Cholesterol/me [Metabolism]<br/>Female<br/>Genome-Wide Association Study<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors/ae [Adverse Effects]<br/>Middle Aged<br/>Polymorphism, Single Nucleotide/ge [Genetics]<br/>Postmenopause<br/>Risk Assessment<br/>Risk Factors<br/>Women's Health
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Health Research Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article